SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons sharp rebound is being linked by traders to Morgan Stanley naming it a top pick on AWS growth and AI prospects, as well as AWS making its Trainium chips easier for developers to use. Bulls welcome the move and point to cloud and AI momentum, while skeptics question whether it can hold amid heavy capex and recent volatility.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. It assembles a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. The company was founded in October 2017 and is headquartered in Watertown, MA.

Disc Medicine Inc

Disc Medicine shares surged after bitopertin met all primary and secondary endpoints in the Phase 3 APOLLO trial for erythropoietic protoporphyria, strengthening the case for an FDA resubmission, though approval is still pending. Traders are debating the significance of dizziness reported among treated patients and speculating about a short squeeze amid volatile trading.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

A stronger-than-expected third quarter and an upbeat 2027 EBITDA outlook are driving CLFs rally, with bullish traders anticipating short covering. Others warn the outlook depends on steel prices and remain focused on the companys debt, while some see the move as a sell-the-news bounce.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras is drawing attention amid a steep post-IPO selloff, with traders citing insider share sales and upcoming lockup releases as added supply pressure alongside concerns about valuation, growth and its OpenAI exposure. Bears warn of further downside, while bulls argue the decline is overdone and are buying the dip; some also attribute weakness to a broader AI and semiconductor-sector retreat.

Vicor Corp. engages in the design, development, manufacture, and marketing of modular power components. The firm provides complete power systems based upon a portfolio of patented technologies. Its products include AC-DC converters, power systems, and accessories. The company was founded by Patrizio Vinciarelli in 1981 and is headquartered in Andover, MA.

Vicor Corp.

Vicor is drawing attention ahead of its Q3 report after raising its outlook twice, with traders citing higher royalties from its AI-focused Vertical Power Delivery licensing. Bulls see the pullback as a buying opportunity and expect strong results, while others point to the stocks volatility and selling despite the improved outlook.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Reported takeover interest from Lundbeck is driving speculation about a potential bid or bidding war and heightened trading activity. Xeris has said it is not for sale, leaving traders divided between treating the chatter as a credible deal catalyst and focusing on Recorlev growth and XP-8121s pipeline prospects.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Sea is under pressure after a sharp selloff and technical breakdown, with traders citing recent insider share sales and an analyst downgrade as possible catalysts; some also point to weakness in Indonesian and regional markets. Bears fear further declines and criticize management, while bulls argue the business remains fundamentally strong and view the pullback as a buying opportunity.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBios FDA expansion of Anktiva plus BCG to papillary-only bladder cancer, alongside positive long-term trial data, is the main focus. The share-price decline despite those developments has prompted debate over profit-taking, broader biotech weakness and options activity, while some traders allege manipulation without substantiation.

Sunrun, Inc. engages in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems. It sells solar service offerings and installs solar energy systems for homeowners. Customers can access its products through three channels: direct-to-consumer, solar partnerships, and strategic partnerships. The company was founded by Edward Harris Fenster, Robert Nat Kreamer, and Lynn Michelle Jurich in January 2007 and is headquartered in San Francisco, CA.

Sunrun Inc

Sunrun is drawing attention amid a persistent selloff and weak solar-sector sentiment, with traders pointing to interest-rate sensitivity, policy and financing concerns, and analyst target cuts. The debate is whether its AI data-center, battery-storage and virtual-power-plant initiativesand perceived high short interestcould offset those pressures; some traders view them as a potential turnaround catalyst, while others remain bearish.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

Goldman Sachs upgrade of CoreWeave to Buy prompted hopes for a rebound after a sharp selloff, but traders remain focused on the companys debt burden, bond-market stress, and ability to finance expansion. Bulls point to AI demand and contracted backlog as support, while bears argue those commitments may not translate into enough cash flow to cover financing needs.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

STZ Stock Looks To Snap 7 Weeks Of Losses: Why Goldman Sachs Is Bullish Despite Slashing Price Target

Equity

Goldman Sachs keeps a ‘Buy’ rating on Constellation Brands, citing stronger brand momentum and solid earnings.  


Should You Invest in the First Trust Consumer Staples AlphaDEX ETF (FXG)?

Is First Trust Consumer Staples AlphaDEX ETF (FXG) a Strong ETF Right Now?

CPB Stock Heads For Worst Week Since March: Jefferies Sees 2027 'Shaping Up As A Difficult Year' After Dividend Cut 

Jefferies lowered its price target for Campbell's, citing challenging fiscal 2027 guidance.


ETFs to Gain as Trump Waives Off Tariffs on Beef Imports Temporarily

Trump's 90-day beef tariff waiver could lower costs for fast-food chains and meat distributors, benefiting ETFs with exposure to these companies.

GIS Stock Eyes Second Week Of Gains: Jefferies Sees Savings Upside For General Mills Amid Consumer Pressure 

Jefferies raised its price target on GIS and highlighted a focus on brand investments.  


CPB Stock Slips Premarket After Earnings – But Retail Still Sees Campbell’s As A 'Defensive Play' 

Bank of America slashed its price target on CPB from $20 to $18.


First Trust Exchange-Traded AlphaDEX Fund - First Trust Consumer Staples AlphaDEX Fund

Neutral Sentiment

<ul class="summary-bullets"><li>Goldman Sachs cut Constellation Brands’ price target to $155 from $180, still implying a 31% upside.&nbsp;</li><li>Constellation said September trends could lift FY27 results toward the upper end of guidance.&nbsp;</li><li>Constellation CEO Nicholas Fink sees renewed beer growth through stronger marketing.&nbsp;</li></ul><p>Constellation Brands (STZ) stock is looking to break a seven-week losing streak, and Goldman Sachs isn’t giving up on the beer giant. Despite slashing its price target, the firm kept its Buy rating as CEO Nicholas Fink points to renewed brand momentum, emerging products and aggressive marketing to reignite growth.&nbsp;</p><p><a href="https://stocktwits.com/symbol/STZ">Constellation Brands stock</a> edged 0.65% lower overnight Wednesday after a 2% gain in regular session. The stock has rallied nearly 5% so far this week and is on track for its best week since June.&nbsp;</p><h2 class="st-heading-2">Goldman Sachs Stays Bullish On Constellation Brands Despite Target Cut&nbsp;</h2><p>Goldman Sachs cut its Constellation Brands price target to $155 from $180 but kept its ‘Buy’ rating. The new target still suggests about 31% upside from the stock’s last close, showing the firm remains positive on the shares.&nbsp;</p><p>Constellation Brands&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/stz-stock-falls-as-modelo-and-corona-lose-volume-full-year-profit-outlook-holds/cZDtS6VRBlk">reported</a> comparable earnings of $3.74 per share, beating analysts' consensus estimate of $3.60, according to Fiscal.ai data. Also, management offered investors another reason for optimism during the earnings call. Constellation said continued improvement in September could allow the company to finish fiscal 2027 near the top of its comparable earnings outlook of $11.20 to $11.90 per share. Goldman Sachs said it was encouraged by that possibility.</p><h2 class="st-heading-2">Constellation Targets A Beer Growth Revival&nbsp;</h2><p>Constellation Brands CEO Nicholas Fink said the company sees more ways to boost beer sales through stronger marketing, better brand execution and new products.&nbsp;</p><p>“We're a growth business and we need to get that engine humming again. That's going to take sustained work across marketing, brand positioning, commercialization, products, and packs,” Fink said during the earnings call.</p><p>"Take Corona, for example. We put more behind Corona and got more focused on granular execution. It's not a brand that requires awareness driving; it's a brand that requires saliency. And we're seeing green shoots already. If I look at Circana data, our 12-week is better than our 52-week and our 4-week is better than our 1-week. I'm not satisfied with where it is, but it's trending in the right direction—a lot better than it was a year ago."&nbsp;</p><p>Fink said Modelo is also showing signs of improvement, with the company targeting Hispanic consumers and using major sports events like football season to reach more U.S. customers.&nbsp;</p><h2 class="st-heading-2">STZ Stock: Retail Stance</h2><p>On Stocktwits, retail sentiment around the stock fell to ‘neutral’ from ‘extremely bullish’ territory the previous day.&nbsp;</p><p>A user&nbsp;<a href="https://stocktwits.com/InvestingWithRob/message/666007841">said</a>, “They have a 2.5 billion share buyback authorization that represents about 12% of the market cap.”&nbsp;</p><p>STZ stock has declined over 14% year-to-date.&nbsp;</p><p>Also see:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/capr-stock-rises-nearly-5-as-capricor-presents-heart-data-for-deramiocel-ahead-of-november-fda-decision/cZDvAk3RBZO">CAPR Stock Rises Nearly 5% As Capricor Presents Heart Data For Deramiocel Ahead Of November FDA Decision</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, bottles of Corona beer are displayed.

Constellation Brands (STZ) stock is looking to break a seven-week losing streak, and Goldman Sachs isn’t giving up on the beer giant. Despite slashing its price target, the firm kept its Buy rating as CEO Nicholas Fink points to renewed brand momentum, em

First Trust Exchange-Traded Fund III - First Trust Consumer Staples AlphaDEX Fund

VanEck Morningstar Wide Moat Value ETF

Constellation Brands Inc

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$61.59
Prev Close	$62.20
Open	$61.76
Dividend Yield	N/A
50-Day Moving Average	$62.46
Beta	N/A
Avg. Volume	12,461.70
PE Ratio	N/A

52-Week High	$69.50
52-Week Low	$57.29
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

FXG Fundamentals